Adma Biologics, Inc. ADMA
We take great care to ensure that the data presented and summarized in this overview for ADMA BIOLOGICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADMA
View all-
Black Rock Inc. New York, NY18.6MShares$375 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$364 Million0.01% of portfolio
-
State Street Corp Boston, MA13MShares$262 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.6MShares$254 Million0.05% of portfolio
-
Morgan Stanley New York, NY8.6MShares$173 Million0.01% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL6.58MShares$132 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA5.38MShares$108 Million0.01% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.26MShares$106 Million0.1% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny4.45MShares$89.6 Million0.22% of portfolio
-
Awm Investment Company, Inc. New York, NY4.45MShares$89.5 Million12.17% of portfolio
Latest Institutional Activity in ADMA
Top Purchases
Top Sells
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Insider Transactions at ADMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 27
2024
|
Steve Elms |
BUY
Exercise of conversion of derivative security
|
Indirect |
9,000
+0.42%
|
$90,000
$10.8 P/Share
|
|
Nov 22
2024
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
48,967
-2.4%
|
$1,028,307
$21.1 P/Share
|
|
Nov 22
2024
|
Brad L. Tade CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
15,000
-7.0%
|
$315,000
$21.15 P/Share
|
|
Sep 30
2024
|
Adam S Grossman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,752
-1.06%
|
$413,288
$19.99 P/Share
|
|
Sep 30
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
2,647
-0.59%
|
$50,293
$19.99 P/Share
|
|
Sep 09
2024
|
Lawrence P. Guiheen |
SELL
Open market or private sale
|
Direct |
9,000
-5.52%
|
$162,000
$18.47 P/Share
|
|
Sep 09
2024
|
Lawrence P. Guiheen |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+5.23%
|
$90,000
$10.8 P/Share
|
|
Aug 30
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Open market or private sale
|
Direct |
24,150
-5.1%
|
$386,400
$16.9 P/Share
|
|
Aug 30
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
BUY
Exercise of conversion of derivative security
|
Direct |
24,150
+1.28%
|
$72,450
$3.9 P/Share
|
|
Aug 29
2024
|
Jerrold B Grossman |
SELL
Open market or private sale
|
Direct |
136,861
-22.65%
|
$2,326,637
$17.27 P/Share
|
|
Aug 29
2024
|
Jerrold B Grossman |
BUY
Exercise of conversion of derivative security
|
Direct |
136,861
+6.61%
|
$821,166
$6.81 P/Share
|
|
Aug 27
2024
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
389,356
-15.9%
|
$6,619,052
$17.29 P/Share
|
|
Aug 27
2024
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
389,356
+7.18%
|
$1,168,068
$3.14 P/Share
|
|
Aug 26
2024
|
Adam S Grossman President and CEO |
SELL
Open market or private sale
|
Direct |
236,889
-10.31%
|
$4,027,113
$17.69 P/Share
|
|
Aug 26
2024
|
Adam S Grossman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
236,889
+2.1%
|
$1,421,334
$6.9 P/Share
|
|
Aug 23
2024
|
Young Kwon |
SELL
Open market or private sale
|
Direct |
60,000
-19.9%
|
$1,080,000
$18.26 P/Share
|
|
Jul 24
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
2,502
-0.55%
|
$32,526
$13.58 P/Share
|
|
Jul 24
2024
|
Brad L. Tade CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
72,400
+25.24%
|
-
|
|
Jun 30
2024
|
Adam S Grossman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,752
-1.05%
|
$239,272
$11.18 P/Share
|
|
Jun 30
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
2,085
-0.46%
|
$22,935
$11.18 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 967K shares |
|---|---|
| Exercise of conversion of derivative security | 805K shares |
| Open market or private sale | 2.52M shares |
|---|---|
| Payment of exercise price or tax liability | 277K shares |
| Bona fide gift | 10K shares |
| Other acquisition or disposition | 460K shares |